Overview IL-23 plays a key regulatory role in the pathogenesis of plaque psoriasis and medications targeting IL-23 have been shown to be effective for people with this skin condition.1–6 Tildrakizumab is a high-affinity, anti-IL-23p19 monoclonal antibody approved for treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.1 Trials showing efficacy and safety1,2,7 of tildrakizumab up to 64 weeks have been published, and long-term trials have been...
